Current Report Filing (8-k)
May 21 2019 - 7:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2019
MIRAGEN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36483
|
|
47-1187261
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
6200 Lookout Rd.
Boulder, CO
|
|
80301
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (720)
643-5200
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligations of
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.01 par value
|
|
MGEN
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Section 8 Other Events
On May 21, 2019, Miragen Therapeutics, Inc., a Delaware corporation, or the Company, issued a press release announcing data demonstrating that systemic
administration of its second-generation
microRNA-29
mimic, the Companys
pre-clinical
micro-RNA
targeted therapeutic
candidate for idiopathic pulmonary fibrosis, efficiently reduced extracellular matrix deposition in a series of preclinical studies. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated herein by reference.
Section 9 Financial Statements and Exhibits
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Miragen Therapeutics, Inc.
|
|
|
|
Date: May 21, 2019
|
|
By:
|
|
/s/ Jason A. Leverone
|
|
|
|
|
Jason A. Leverone
|
|
|
|
|
Chief Financial Officer
|
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024